What changed?
Vitruvias Therapeutics has recalled one lot of the medication because testing confirmed the potential for the tablets to be superpotent—meaning they could contain more thyroid hormone than intended.
The recalled product is:
Thyroid Tablets, USP 30 mg — Lot: 504950 — NDC: 69680-166-00 — Expiration date: September 30, 2026
The lot was distributed nationwide in the United States between January 31 and September 30, 2025.
Who is affected?
Why does this matter?
Too much thyroid hormone can cause symptoms associated with an overactive thyroid, including weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate and heart-rhythm disturbances.
The FDA says older adults are among those at greater risk from excessive thyroid hormone exposure, particularly with prolonged use.
When?
The recalled lot was distributed nationwide between January 31 and September 30, 2025, and has an expiration date of September 30, 2026.
The recall was posted by the U.S. Food and Drug Administration on August 24, 2026.
What does this mean?
But there's an important instruction here:
Don't simply stop taking the medication.
The FDA specifically says patients taking Thyroid Tablets from the recalled lot should not discontinue use without contacting their healthcare provider for further guidance or a replacement prescription.
The company says it has not received reports of adverse events known to be related to this recall.
So this isn't a reason to panic.
It's a reason to check the bottle.
The Watchdog takeaway
If you take Thyroid Tablets, USP 30 mg:
- 1
Check the lot number
Check whether your prescription is Lot 504950.
- 2
Contact your pharmacist or healthcare provider
If it is, contact your pharmacist or healthcare provider and ask what you should do.
- 3
Don't stop on your own
Don't abruptly stop thyroid medication on your own.
What this does not mean
- This is not a reason to panic — it's a reason to check the bottle.
- The company says it has not received reports of adverse events known to be related to this recall.
- Only one lot is affected: Lot 504950 of Thyroid Tablets, USP 30 mg.
Current status
- CURRENT
The FDA posted the Vitruvias Therapeutics recall of one lot of Thyroid Tablets, USP 30 mg (Lot 504950) due to potential superpotency.
Official sources
U.S. Food and Drug Administration:
About this information
Senior Life Watchdog provides general public information and is not a government agency, law firm, financial advisory service, or healthcare provider. This information is intended to help readers understand changes and locate official resources. Rules can change and individual eligibility depends on your circumstances. Always verify important information with the appropriate government agency or qualified professional before making financial, legal, or healthcare decisions.
Evidence: Strong. This is an FDA-posted recall involving a specific medication lot because of potential superpotency. Source: U.S. Food and Drug Administration, August 24, 2026.
Last verified: September 25, 2026
We’ll update this page when official information changes.
VERIFY THE INFORMATION
- Source:
- U.S. Food and Drug Administration
- Official publication:
- Vitruvias Therapeutics recall of Thyroid Tablets, USP 30 mg
- Last verified by Senior Life Watchdog:
KNOW SOMEONE WHO SHOULD SEE THIS?
If this information could help someone you know, share this alert with them.
GET THE WATCHDOG ALERT
Important changes. Scam warnings. Benefits updates. Only when something actually matters.
Your email address is used only for Senior Life Watchdog communications. We do not sell or share subscriber information.